IMPAX LABORATORIES INC (IPXL) > Segments [Rocket]

In millions, except per share items	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues:
Epinephrine Auto-Injector family (generic Adrenaclick®)	113.9	91.6
Oxymorphone HCI ER family	68.6	72.7	59.2	65.3
Budesonide family	51.5
Zomig family	51.1
Fenofibrate family		64.0	93.5	111.6
Diclofenac Sodium Gel family (generic Solaraze®)		69.0	148.6
Sevelamer Carbonate family (generic Renvela®)				82.0
Amphetamine Salts ER (CII) family (generic Adderall®)			106.3	115.4
Other	263.9	309.1	303.4	174.8
Impax Generics revenues	549.1	606.3	710.9	549.1	398.3
Revenue growth [+]	-9.4%	-14.7%	29.5%	37.8%
Epinephrine Auto-Injector family (generic Adrenaclick®)	24.4%
Oxymorphone HCI ER family	-5.6%	22.8%	-9.4%
Fenofibrate family		-31.5%	-16.2%
Diclofenac Sodium Gel family (generic Solaraze®)		-53.5%
Amphetamine Salts ER (CII) family (generic Adderall®)			-7.9%
Gross profit	549.1	606.3	710.9	549.1	398.3
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative	28.3	20.5	29.6	17.1	17.7
Research and development	63.2	62.0	52.5	40.9	41.4
EBIT	-265.2	-386.4	169.5	225.2	68.9
EBIT margin	-48.3%	-63.7%	23.8%	41.0%	17.3%
Pre-tax income					68.9
Pre-tax margin					17.3%

Revenue Mix	70.8%	73.5%	82.6%	92.1%	77.9%
EBIT Mix			243.6%	253.6%